Abstract:Gene expression signatures predictive of chemotherapeutic response have the potential to greatly extend the reach of precision medicine by allowing medical providers to plan treatment regimens on an individual basis for patients with and without actionable mutations. Most published gene signatures are only capable of predicting response for individual drugs, but currently, a majority of chemotherapy regimens utilize combinations of different agents. We propose a unified framework, called the chemogram, that uses predictive gene signatures to rank the relative predicted sensitivity of different drugs for individual tumor samples. Using this approach, providers could efficiently screen against many therapeutics to identify the drugs that would fit best into a patient's treatment plan at any given time. This can be easily reassessed at any point in time if treatment efficacy begins to decline due to therapeutic resistance. To demonstrate the utility of the chemogram, we first extract predictive gene signatures using a previously established method for extracting pan-cancer signatures inspired by convergent evolution. We derived 3 signatures for 3 commonly used cytotoxic drugs (cisplatin, gemcitabine, and 5-fluorouracil). We then used these signatures in our framework to predict and rank sensitivity among the drugs within individual cell lines. To assess the accuracy of our method, we compared the rank order of predicted response to the rank order of observed response (fraction of surviving cells at a standardized dose) against each of the 3 chemotherapies. Across a majority of cancer types, chemogram-generated predictions were consistently more accurate than randomized prediction rankings, as well as prediction rankings made by randomly generated gene signatures. In addition to the chemogram's ability to rank relative sensitivity for any given tumor, this framework is easily scalable for any number of drugs for which a predictive signature exists. We repeated the process described above for 10 drugs and found that the accuracy of the predicted sensitivity rankings was maintained as the number of drugs in the chemogram's screen increased. Our proposed framework demonstrates the ability of transcriptomic signatures to not only predict chemotherapeutic response but correctly assign rankings of drug sensitivity on an individual basis. With further validation, the chemogram could be easily integrated in a clinical setting, as it only requires gene expression data, which is less expensive than an extensive drug screen and can be performed at scale.

Characterization of Expression-Based Gene Clusters Gives Insights into Variation in Patient Response to Cancer Therapies

Identification of Gene Expression Pattern Related to Breast Cancer Survival Using Integrated TCGA Datasets and Genomic Tools.

Telomere-Associated Gene Signatures Correlate with Prognosis, Tumor Microenvironment, and Chemosensitivity in Breast Cancer.

Abstract 1671: Characterization of a Gene Signature Predictive of Cancer Patient Survival Prognosis and Chemo-Response

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis

Analysis of Chemotherapy Response Programs in Ovarian Cancers by the Next-Generation Sequencing Technologies

Factors related to tumor response rate from TCGA three omics data—variants, expression, methylation

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Gene Expression Profiles As Biomarkers for the Prediction of Chemotherapy Drug Response in Human Tumour Cells

Immune Gene Patterns and Characterization of the Tumor Immune Microenvironment Associated with Cancer Immunotherapy Efficacy

Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing

Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

Prediction of Response to Radiotherapy by Characterizing the Transcriptomic Features in Clinical Tumor Samples Across 15 Cancer Types

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade

Identification of hub genes to determine drug-disease correlation in breast carcinomas

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

Personalizing chemotherapy drug selection using a novel transcriptomic chemogram

Gene Mutations Associated With Clinical Characteristics in the Tumors of Patients With Breast Cancer

Transcriptional Characterization of Resistance in Early Drug Response